Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: Leveraging real-world experience from Belgium

Matt D Wasserman; Heather L Sings; Michele R Wilson; Maarten J Postma; Marie-Claude Breton; Cheryl McDade; Raymond A Farkouh

doi:doi:10.1007/s40121-018-0222-1

Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada

Leveraging real-world experience from Belgium

Wasserman, M. D., Sings, H. L., Wilson, M. R., Postma, M. J., Breton, M-C., McDade, C., & Farkouh, R. A. (2018). Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: Leveraging real-world experience from Belgium. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-018-0222-1

Copy citation

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Article

Development of a novel shared decision making aid for primary immunodeficiency diseases

Article

Community overdose surveillance

Article

Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada

Publications Info

Recent Publications

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Development of a novel shared decision making aid for primary immunodeficiency diseases

Community overdose surveillance

Epigenetic biomarkers for smoking cessation

Partner With Us

Site